Longeveron (LGVN) Cost of Revenue (2020 - 2026)
Longeveron's (LGVN) quarterly Cost of Revenue came in at $134000.0 in Q1 2026, up 26.42% year-on-year from $106000.0 in Q1 2025, and up 24.07% quarter-over-quarter from $108000.0 in Q4 2025.
Longeveron (LGVN) Cost of Revenue (2020 - 2026) Analysis & Trends
Longeveron's Cost of Revenue history runs 7 years deep, the most recent figure standing at $134000.0 for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 26.42% year-over-year to $134000.0 in Q1 2026; TTM through Mar 2026 was $424000.0, a 7.61% increase from a year earlier, with the FY2025 full-year figure at $396000.0, down 22.05% from the prior year.
- Cost of Revenue grew to $134000.0 in Q1 2026 per LGVN's latest filing, from $108000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $306000.0 in Q2 2022 and bottomed at $12000.0 in Q3 2025.
- The 5-year median for Cost of Revenue is $124000.0 (2023), against an average of $140294.1.
- Across the five-year window, Cost of Revenue soared 154.41% in 2022 and tumbled 86.81% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $176000.0 in 2022, then tumbled by 63.07% to $65000.0 in 2023, then rose by 12.31% to $73000.0 in 2024, then soared by 47.95% to $108000.0 in 2025, then increased by 24.07% to $134000.0 in 2026.
- Per Business Quant, the three latest LGVN Cost of Revenue figures stand at $134000.0 (Q1 2026), $108000.0 (Q4 2025), and $12000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | 134,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134,000.00 |
| Mar 31, 2026 | 134,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Dec 31, 2025 | 108,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Sep 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 170,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Dec 31, 2023 | 65,000.00 |
| Dec 31, 2023 | 65,000.00 |